The TRANSINT™ platform directs safe, efficient delivery of biological payloads across epithelial cells to local GI submucosal tissue, the epicenter of the immune system for engaging mucosal immunology pathways to correct dysregulation. The technology is also capable of releasing payloads into the bloodstream.
Our uniquely formulated, stable biological molecules transit through the intestinal lumen until contact with the epithelial surface. Upon translocation across the GI epithelia, the constructs selectively present therapeutic payloads to targets within the local intestinal submucosal/gut- associated lymphatic tissue or for release into the hepatic-portal system and downstream systemic circulation. This route of administration provides privileged access to the vast immune system biology located along the GI tract as well as multiple hepatic-portal targets.
The TRANSINT™ microbe-inspired protein scaffolding, cellular translocation and targeting platform will enable the next-generation of biopharmaceuticals with superior pharmacological properties, precision, localized targeting and enhanced safety profiles.